Amgen's brodalumab improves psoriatic arthritis signs and symptoms in Phase 2 study

The new brodalumab drug from Amgen is effective in reducing the symptoms and signs of psoriatic arthritis. The effectiveness of the antibody is advocated by a new Phase 2 study.